Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/o7/96 \ Origin: Appendix 5 \ Amended o 1/o7/98, o 1/o9/99, o 1/o7/00, 30/09/01, 11/o3/02, o 1/o1/03, 24/10/05, o 1/o8/12, o 4/o3/13$ 

	· · · · · · · · · · · · · · · · · · ·	
	Recce Ltd	
ABN		
	73 124 849 065	
We (th	e entity) give ASX the following	information.
	- All issues t complete the relevant sections (attach	sheets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary fully paid shares ( <b>Ordinary Shares</b> )
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	5,408,487 Ordinary Shares
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary Shares  • 5,408,487 ordinary Shares will rank pari passu with existing Ordinary Shares

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

The Ordinary Shares rank pari passu with existing Do the \*securities rank equally in 4 **Ordinary Shares** all respects from the +issue date with an existing +class of quoted +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment \$0.175 per share resulting in the Company Issue price or consideration 5 receiving an aggregate consideration of \$946,500 The purpose of the issue of the Ordinary Shares is 6 Purpose of the issue to raise funds for the FDA IND application, (If issued as consideration for the acquisition of assets, clearly Administrative Expenses and Working identify those assets) Capital/recapitalization of balance sheet ahead of targeted first human trials tests. 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed N/A 6c Number of \*securities issued without security holder approval under rule 7.1

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	5,408,487 fully paid ordinary shares under Exception 15
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7,815,097 remaining capacity under rule 7.1 7,724,587 remaining capacity under rule 7.1A
7	<sup>+</sup> Issue dates	25 October 2017
7		2) 000001 201/
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	
	Cross reference: item 33 of Appendix 3B.	

<sup>+</sup> See chapter 19 for defined terms.

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
42,701,445	Ordinary

9 Number and <sup>+</sup>class of all <sup>+</sup>securities not quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	+Class		
641,000	Options		
59,880	Tranche 1 Options		
104,167	Tranche 2 Options		
109,569	Tranche 3 Options		
42,810,081	Ordinary escrowed until 15/1/2018		
8,754,423	Class B Performance Shares escrowed until 15/1/2018		
8,754,423	Class C Performance Shares escrowed until 15/1/2018		
8,754,423	Class D Performance Shares escrowed until 15/1/2018		
1	Convertible Security with Face Value of \$200,000		

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

#### Part 2 - Pro rata issue

11	Is	security	holder	approval
	req	uired?		

N/A

Is the issue renounceable or nonrenounceable? N/A

Ratio in which the \*securities will be offered

N/A

<sup>+</sup>Class of <sup>+</sup>securities to which the offer relates N/A

N/A

15 <sup>+</sup>Record date to determine entitlements

N/A

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type (tick o	of *securities one)
(a)		+Securities described in Part 1
(b)		All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible

#### Entities that have ticked box 34(a)

securities

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

<sup>+</sup> See chapter 19 for defined terms.

Entities	s that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another transported and identifications)		
	another *security, clearly identify that other *security)		
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number	+Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the †securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	( <del>Director</del> /Company secretary)	Date: .	25 October 2017
Print name:	Peter Williams		

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	76,186,872	
<ul> <li>Add the following:         <ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul> </li> </ul>	1,059,000 shares issued on conversion of Class A Performance Shares.	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period		
"A"	77,245,872	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	11,586,880	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	103,913 shares issued on 25 Nov. 2016 654,715 shares issued on 21 June 2017 641,000 options issued on 21 June 2017 299,401 shares issued on 19 July 2017 59,880 options issued on 19 July 2017 520,833 shares issued on 25 Aug. 2017 104,167 options issued on 25 Aug. 2017 730,460 shares issued on 22 Sept. 2017 547,845 shares issued on 29 Sept 2017 109,569 options issued on 29 Sept. 2017	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	3,771,783	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	11,586,880	
Note: number must be same as shown in Step 2		
Subtract "C"	3,771,783	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	7,815,097	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in Step 1 of Part 1  Stop 2: Coloulate 10% of "A"	77,245,872	
Step 2: Calculate 10% of "A" "D"	0.10  Note: this value cannot be changed	
Multiply "A" by 0.10	7,724,587	
010 0-1- 1-1- (FII 11		
7.1A that has already been used  Insert number of †equity securities issued or agreed to be issued in that 12 month	of placement capacity under rule  Nil	
7.1A that has already been used		

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	7,724,587	
Subtract "E"  Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	7,724,587  Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.